Myeloma Expert Brian Durie Discusses the ASPIRE Trial
Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma.
Brian G.M. Durie, an expert in multiple myeloma at Cedars-Sinai in Los Angeles, Calif., and chairman of the International Myeloma Foundation, discusses the ASPIRE trial for patients with relapsed myeloma. The study evaluated adding Kyprolis (carfilzomib) to the combination of Revlimid (lenalidomide) and the steroid dexamethasone.
"This was a very important observation just to show the substantial impact of using three drugs versus two drugs," Durie says. "And so using a novel combination of three drugs, you could add basically one year to the remission duration and possibly even longer to the survival of the patient."
